139 related articles for article (PubMed ID: 33442873)
1. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
[TBL] [Abstract][Full Text] [Related]
2. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
[TBL] [Abstract][Full Text] [Related]
3. Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma.
Pruss M; Dwucet A; Tanriover M; Hlavac M; Kast RE; Debatin KM; Wirtz CR; Halatsch ME; Siegelin MD; Westhoff MA; Karpel-Massler G
Br J Cancer; 2020 Apr; 122(8):1146-1157. PubMed ID: 32115576
[TBL] [Abstract][Full Text] [Related]
4. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
[TBL] [Abstract][Full Text] [Related]
5. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells.
Al Madhoun A; Haddad D; Al Tarrah M; Jacob S; Al-Ali W; Nizam R; Miranda L; Al-Rashed F; Sindhu S; Ahmad R; Bitar MS; Al-Mulla F
Sci Rep; 2021 Jun; 11(1):11893. PubMed ID: 34088951
[TBL] [Abstract][Full Text] [Related]
6. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
[TBL] [Abstract][Full Text] [Related]
9. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
10. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
[TBL] [Abstract][Full Text] [Related]
11. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.
Farmaki E; Nath A; Emond R; Karimi KL; Grolmusz VK; Cosgrove PA; Bild AH
Elife; 2023 Sep; 12():. PubMed ID: 37772709
[TBL] [Abstract][Full Text] [Related]
12. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
Zhao R; Li Y; Gorantla S; Poluektova LY; Lin H; Gao F; Wang H; Zhao J; Zheng JC; Huang Y
Antiviral Res; 2019 Aug; 168():134-145. PubMed ID: 31158413
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
[TBL] [Abstract][Full Text] [Related]
14. Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.
Amoroso F; Glass K; Singh R; Liberal F; Steele RE; Maguire S; Tarapore R; Allen JE; Van Schaeybroeck S; Butterworth KT; Prise K; O'Sullivan JM; Jain S; Waugh DJ; Mills IG
Sci Rep; 2021 Feb; 11(1):4252. PubMed ID: 33608585
[TBL] [Abstract][Full Text] [Related]
15. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
Tu YS; He J; Liu H; Lee HC; Wang H; Ishizawa J; Allen JE; Andreeff M; Orlowski RZ; Davis RE; Yang J
Neoplasia; 2017 Oct; 19(10):772-780. PubMed ID: 28863346
[TBL] [Abstract][Full Text] [Related]
16. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.
He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975
[TBL] [Abstract][Full Text] [Related]
17. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
18. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
